Economic information and modeling reportBudget impact modelResults
Scenario analyses
2 evidence topics · 4 sources
Budget impact model of ficerafusp alfa: scenario analyses
No evidence found.
Scenario and sensitivity analyses recommended for budget impact analysis
Sensitivity analyses in United States cost-effectiveness analyses of first-line regimens
“Sensitivity analyses showed a high cost-effectiveness probability for pembrolizumab at the $100,000/QALY threshold.” (opens the original PubMed page at this quote in a new tab)View highlighted excerpt for this quote
“Variations in HR for OS and body weight were generally the strongest influences on ICERs.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote
“Given a WTP threshold of $150,000 per QALY, the probability of the EXTREME regiment being cost-effective compared with nivolumab and ipilimumab, was 64%.” (opens the original PMC page at this quote in a new tab)View highlighted excerpt for this quote